155 results about "Lupus nephritis" patented technology

The present invention provides a therapeutic or prophylactic agent as a substitute for conventional steroids or immunosuppressive agents to treat or prevent systemic erythematosus, glomerulonephritis, lupus nephritis, idiopathic thrombocytopenic purpura or autoimmune anemia. The agent comprises a retinoic acid receptor agonist, specifically a retinoic acid receptor subtype alpha (RARalpha) agonist, including for example:(1) carboxylic acid compounds having condensed rings represented by the following formula: (wherein the rings L and M are condensed, are the same as or different from each other, and represent an aromatic hydrocarbon which may have a substituent group or a heterocycle which may have a substituent group; the rings A and B are independent of each other and represent an aromatic hydrocarbon ring or heterocycle which may have a substituent group; and D represents a carboxyl group which may have a protective group),(2) 4-{[(3,5-bistrimethylsilylphenyl)carbonyl]amino}benzoic acid, 4-{2-[5-(3-methoxymethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)pyrrolyl]}benzoic acid, etc.

This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and / or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and / or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and / or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and / or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

The invention relates to novel methods of using 2-methylene-19-nor-20(S)-1,25-dihydroxyvitamin D3 to prevent renal disease, particularly Lupus nephritis, in a subject at risk of developing renal disease. Methods of preventing symptoms of renal disease, such as proteinuria, splenomegaly or glomerular damage are also provided. Methods of treating symptoms of renal disease, including proteinuria and splenomegaly, are also provided.

Methods for the detection of active lupus nephritis (LN) and worsening renal disease activity and / or active LN in patients diagnosed with systemic lupus erythematosus, using a panel of biomarkers including transferrin (Tf), ceruloplasmin (Cp), alpha-1-acid glycoprotein (AGP1), lipocalin-like prostaglandin D synthetase (L-PGDS), and urinary neutrophil gelatinase associated lipocalin (UNGAL).

The present invention relates to a medicine for curing kidney diseases. Said medicine is a Chinese medicine capsule preparation made from 20 Chinese medicinal materials of cooked rehmannia root, silkworm, bupleurum root, Chinese yam, astragalus root, leech and others through the processes of conventional water and alcohol double extraction. Said medicine can be used for curing the diseases of acute and chronic nephritis, purpuric nephritis, hepatitis B related nephritis, lupoid nephritis, nephrotic syndrome, renal insufficiency and diabetic nephritis, etc. Its cure rate is up to 92%.

Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and / or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

The present disclosure relates to methods for treating lupus nephritis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007).

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

This invention relates to methods for treatment of nephritis associated with immune complex disease using anti-CD40L compounds. According to one embodiment of this invention, anti-CD40L compounds are administered to a patient with immune complex disease who has received a kidney allograft, to inhibit the development of immune complex glomerulonephritis within the grafted kidney.

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and / or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and / or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating lupus or decreasing autoantibody titer by administration of a non-depleting CD4 antibody are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and / or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.

The invention relates to a mycophenolic acid derivative as shown in a formula V and a pharmaceutically acceptable salt thereof, wherein L is -O-R2, -QCOOR2 or -QCONR2R3, Q is alkylene of C1 to C10 or alkenylene of C1 to C6, and -O-R1, or -O-*M+. The invention further relates to a pharmaceutical composition containing the mycophenolic acid derivative, the pharmaceutically acceptable salt and pharmaceutical adjuvants, a preparation method of the mycophenolic acid derivative and the pharmaceutically acceptable salt, and an application of the mycophenolic acid derivative and the pharmaceutically acceptable salt in immunosuppressant drugs, especially in preparing drugs for treating organ transplants such as skin transplant, liver transplant and heart transplant, and autoimmune diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis, lupus nephritis, IgA nephritis, glomerulus nephritis, etc.

The invention discloses application of coptisine shown as general formula (I) as shown in the specification and pharmaceutically acceptable salt of the coptisine in preparing a medicine for preventing and / or treatingSLE (systemic lupus erythematosus) and complications of SLE.The application has the benefits that the coptisine has pharmacological actions of reducing an in-vivo autoantibody expression level of a mouse with lupus, improving an immunologic function, reducing immune complex sedimentation in a kidney tissue of the mouse with the lupus and improving a kidney function of the mouse with the lupus, and effects of protecting a spleen function of the mouse with the lupus, protecting a vascular endothelium function of the mouse with the lupus, reducing blood pressure and improving vascular activity of the mouse with the lupus.The coptisine is a monomeric compound extracted from a common traditional Chinese medicine, namely rhizoma coptidis, has the advantages of low toxicity, simple extraction technology and the like, is wide in raw material resource, has good application and development prospects and is a relatively perfect novel traditional Chinese medicine monomer for treating the SLE, and the complications of the SLE such as immune dysfunction, lupus nephritis, lupus spleen injury, lupus atherosclerosis and lupus hypertension.

The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and / or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders.

The invention relates to new substituted heteroaryls of formula 1or of formula 1′wherein A is either N or CH,wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl,wherein Y is selected from —O— or —CH2—,and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof,and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

The invention relates to a Chinese medicine for treating the systemic lupus erythematosus, particularly the lupus nephritis and a method for preparing the same. The medicine consists of the following components of oldenlandia diffusa, barbat skullcap, redroot gromwell, glutinous rehmannia, root of red-rooted salvia, motherwort and scorpion. The medicine has effects of clearing away the heat-evil and expelling superficial evils and activating blood circulation to dissipate blood stasis and is mainly used to treat the systemic lupus erythematosus, particularly the lupus nephritis; moreover, by matching Western medicines such as glucocorticoid and immunodepressant, etc., the medicine can be used to jointly treat the systemic lupus erythematosus, which can improve the effect of the hormone and the immunodepressant in curing the systemic lupus erythematosus, lower the incidence rate of infecting the complication, lower the recurernce rate and the death rate and have the important clinical meaning. The medicine of the invention can be made in all medicament forms for clinical use, including the powder, the medicinal broth, the mixture, the oral taking liquid, the capsule, the pelletized granule and the concentrated pill, etc.

The present disclosure provides a method for treating and / or preventing nephrotic syndrome, such as but not limited to MCD and MN, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

The present invention provides a method of treating a subject afflicted with lupus nephritis comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.

The invention discloses a lactococcus lactis subsp. Lactis HFY14 and application thereof, and belongs to the technical field of biology, the lactococcus lactis subsp. Lactis is named as HFY14, the preservation number is CGMCC No.16647, the strain is separated from naturally fermented yoghurt, and the strain has the advantages that the strain can be used for preparing the lactococcus lactis subsp. Lactis HFY14 and the application of the lactococcus lactis subsp. Lactis HFY14; animal experiments, histopathologic observation and other experiments prove that the renal dysfunction of lupus nephritis mice induced by hypophytane through intragastric administration of viable bacterial liquid of the strain can be obviously improved, and the effect is close to that of a medicine prednisone. The invention provides a theoretical basis for the subsequent development and utilization of the lactococcus lactis subsp. Lactis HFY14 and the application of the lactococcus lactis subsp. Lactis HFY14 as a probiotic to improve the renal function of nephropathy, and the strain has the application potential of performing long-term intervention on lupus nephritis to improve the renal function.

The invention aims to provide a molecular marker for diagnosing a lupus nephritis concurrent pulmonary arterial hypertension disease and application thereof. A complement factor h and a complement Bb fragment are used as molecular markers for diagnosis or prediction of the lupus nephritis concurrent pulmonary arterial hypertension disease, so that whether a patient with the lupus nephritis is concurrent with the pulmonary arterial hypertension or the onset risk can be accurately diagnosed or predicted. Compared with the right-sided heart catheterization and other invasive inspection means, the molecular marker and the application thereof are more suitable for clinical popularization.